Evidence map›Paper›PMID 36358790›Full record

ArticleCancers2022

Impact of Microscopic Confirmation on Therapeutic Management of Pancreatic Cancer Patients: Lessons from an Italian Regional Tumor Registry.

Alberto Fantin, Mario Gruppo, Ottavia De Simoni, Sara Lonardi, Chiara Cristofori, Tiziana Morbin, Giulia Peserico, Sabina Grillo, Annalisa Masier, Monica Franco and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alberto FantinDepartment of Gastroenterology, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Mario GruppoUnit of Surgical Oncology of Digestive Tract, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.ORCID 0000-0001-5525-5762
Ottavia De SimoniUnit of Surgical Oncology of Digestive Tract, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.ORCID 0000-0001-8788-5590
Sara LonardiMedical Oncology Unit 3, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.ORCID 0000-0002-7593-8138
Chiara CristoforiDepartment of Gastroenterology, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Tiziana MorbinDepartment of Gastroenterology, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Giulia PesericoDepartment of Gastroenterology, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Sabina GrilloDepartment of Gastroenterology, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Annalisa MasierDepartment of Gastroenterology, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Monica FrancoDepartment of Gastroenterology, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Pierluigi PilatiUnit of Surgical Oncology of Digestive Tract, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Stefano GuzzinatiVeneto Tumor Registry, Azienda Zero, 35128 Padua, Italy.ORCID 0000-0002-4908-5506
Manuel ZorziVeneto Tumor Registry, Azienda Zero, 35128 Padua, Italy.
Massimo RuggeVeneto Tumor Registry, Azienda Zero, 35128 Padua, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Incidence of pancreatic cancer (PC) is increasing worldwide and is set to become the second leading cause of cancer-related death in 2040 with a poor 5-year overall survival (OS). The aim of this study was to analyze the impact of microscopic diagnosis of PC (MiDPC) on diagnostic−therapeutic management and outcome. Methods: The Veneto region (north-eastern Italy) has been covered by a cancer registry (CR) since 1987. Clinical and oncological data about all cases of PC in the Veneto region from 1987 were extracted from the Veneto CR database. Results: In 2018, 1340 incident cases of PC in the Veneto population were registered (4.1% of all malignant tumors), with an increasing trend in females and stable incidence in males. Five-year OS in patients with PC was 8%. The percentage of MiDPC increased from 44% in 2010 to 60% in 2018 (p = 0.001). MiDPC was higher among patients aged < 75 years old (84.4%) compared to those aged ≥75 years old (38.9%), p = 0.001. Between 2010 and 2018, a significant increase in biopsy on the primary neoplasm (24.9% vs. 13%, p < 0.001) was reported. Patients with MiDPC had higher 5-year survival than patients with no MiDPC (12.9% vs. 1.2%, p < 0.001). Conclusions: The implementation of MiDPC was essential to improve diagnostic−therapeutic pathways and consequently the survival of PC patients.

Indexed as

epidemiologyincidencemicroscopic diagnosispancreatic cancersurvival

Identifiers

PMID36358790
PMCPMC9658973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.